Objectives: This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. Methods: From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH (n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. Results: The 5-and 7-year overall survival rates were 97.9 and 91.1%. By PSA levels (PSA ≤ 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5%, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. Conclusions: We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.
Introduction
According to the National Comprehensive Cancer Network (NCCN) guidelines (1), high-risk prostate cancer (PCa) patients have serum prostate-specific antigen (PSA) over 20 ng/ml, a Gleason score (GS) for prostate biopsy specimen over 8 and/or clinical T stage 3 or 4 (cT3-4), which accounts for~15% of PCa patients (2) . For high-risk PCa patients, the NCCN guidelines recommend several treatment options, including radical prostatectomy (RP) with extended pelvic lymph node dissection (PLND) or various radiotherapeutic modalities, including external beam radiotherapy (EBRT) such as three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiation therapy (IMRT) with androgen deprivation therapy (ADT) and the combination of EBRT and brachytherapy with or without ADT. There are some studies regarding the clinical outcomes of RP compared with radiotherapeutic modalities for high-risk PCa (3, 4) . Currently, for those patients, we perform tri-modality therapy combining neoadjuvant ADT, EBRT (such as 3D-CRT) and high dose rate brachytherapy (HDR-BT, called NEH), IMRT with ADT or RP with extended PLND.
In this study, we retrospectively analyzed the association between PSA recurrence and clinical factors of high-risk PCa patients treated with NEH, as well as those treated with IMRT or RP at the same time in order to investigate the clinical benefit of NEH.
Methods

Patients and methods
Patients
This study was approved by the institutional review board of Saitama Medical University International Medical Center (SIMC, approval: # 16-165 for NEH vs. IMRT, # 16-234 for NEH vs. RP). From April 2007 to December 2012, patients were diagnosed as high (including very high)-risk localized PCa according to the NCCN guideline: PSA ≥ 20 ng/ ml, biopsy GS ≥ 8 and/or more than cT3a. The patients underwent either neoadjuvant ADT followed by a combination of 3D-CRT and HDR-BT (NEH group, n = 192), RP (RP group, n = 167) or IMRT (IMRT group, n = 109). Treatment was basically decided by patient preference; however, patients with prostate enlargement (>50 ml) and/or severe urinary symptoms were not indicated for HDR-BT.
Treatment modalities
In our protocol, NEH was serially accomplished. Of note, one patient underwent only 3D-CRT and HDR-BT as he refused neoadjuvant ADT. ADT was performed by a luteinizing hormone releasing hormone analog and/or antiandrogens. Median duration of neoadjuvant ADT was 3.9 (2.7-6.1) months.
Regarding radiotherapy, the gross tumor volume was defined as the prostate and, if a patient had T3 or T4 disease, the radiographically visible tumor. The clinical target volume (CTV) included the prostate, periprostatic tissue that encompassed the prostate with a 3 mm margin while excluding the rectum and the proximal site of the seminal vesicles (generally 2 cm in length). When the tumor infiltrated the seminal vesicles (T3b), the CTV included the whole seminal vesicles. In EBRT (3D-CRT and IMRT), the planning target volume (PTV) was created by adding a 5 mm safety margin anteriorly, superiorly, inferiorly and laterally to the CTV and a 3-4 mm margin posteriorly, for organ motion and set-up uncertainties. In HDR-BT, the PTV was equal to the CTV (5). 10-MV X-rays were used for EBRT. The bilateral arc rotation technique was used for 3D-CRT, and the dynamic multileaf collimator technique was used for IMRT. A total dose of 39 Gy in 13 fractions (~2.5 weeks) was administered to the PTV in 3D-CRT, and a total dose of 78 Gy (range: 72.9-80.3) in 39 fractions (range: 36-39,~8 weeks) was delivered in IMRT. Patients in the NEH group received HDR-BT within 1 week of EBRT (3D-CRT) completion. In HDR-BT, an 192 Ir source was used. After lumbar anesthesia, the interstitial needle applicators were inserted into the CTV under the guidance of transrectal ultrasonography. HDR-BT was administered twice a day at an interval of 6 , with the total prescription dose to the PTV of 18 Gy in two fractions. Because different doses and fractionation schedules were used, the total doses to the PTV of the two treatments were compared using the biologically equivalent dose (BED) in 2 Gy daily fractions (Gy EQD2 ) (5) . When the α/β ratio of PCa was presumed to be 1.5 Gy (6), the BEDs to the PTV for the combination of 3D-CRT and HDR-BT, and IMRT were calculated as 104.1 and 78 Gy EQD2 , respectively.
RP is a method to remove the prostate gland, seminal vesicles and pelvic lymph nodes. We basically performed traditional open prostatectomy through a vertical incision below the belly button.
After biochemical or radiographic recurrence, several salvage therapies, including radiotherapy for local recurrence and systemic ADT, were undertaken based on the physician's judgment without a formula sequential treatment strategy.
Covariates, outcome and definitions Age at date of surgery or radiotherapy, serum PSA level at date of diagnosis (initial PSA; iPSA), Gleason score of prostate biopsy (primary, secondary and sum), clinical T stage and pathological findings of radical prostatectomy were extracted from the clinical records. The relations among the clinical factors and clinical outcomes, including biochemical relapse-free survival (bRFS) and overall survival (OS), were analyzed. Biochemical recurrence in the radiotherapy cohort was defined according to the Phoenix criteria: The PSA level increased more than the nadir PSA level plus 2.0 ng/ml (7). In the RP cohort, it was defined as a serum PSA level over 0.2 ng/ml after surgery. OS was defined as the time from primary treatment to the date of death from any cause or date of censorship from last follow-up.
Statistical analyses
The variables of different groups were compared by Pearson's chisquare test or Kruskal-Wallis one-way analysis of variance on ranks. Survival curves were generated by the Kaplan-Meier method, and curves were compared by log-rank test. P values below 0.05 were considered significant.
Results
Patients' characteristics
Among 468 patients, we retrospectively analyzed 449 patients (Table 1) excluding cases lacking data (cT stage: 18 cases, Gleason score: one case). The median follow-up durations for the IMRT (35.5 months) and RP (54.7 months) groups were shorter than the NEH group (63.9 months). Age was significantly higher in the NEH group than in the RP group (median 72 vs. 69 years, respectively). iPSA was significantly higher in both NEH and IMRT than in RP (median 19.7, 20.8 vs. 15.9 ng/ml). Other pathological data of surgical specimens are shown in Table 1 , for example, extraprostatic extension (EPE), resection margin (RM) and lymph node removal status. Therefore, we investigated as below using the cohort in this retrospective study including some heterogeneous factors.
Clinical outcome after NEH, IMRT or RP for high-risk PCa patients
Five-year bRFS (5y-bRFS) in RP was 51.5%, which was lower than in NEH (79.2%, P < 0.001) and IMRT (62.0%, P < 0.001) (Fig. 1 A) . In addition, 5-and 7-year OS among the NEH, IMRT and RP groups were similar (97.9/91.1, 92.9/92.9 and 95.9/95.9%, respectively) (Fig. 1B) .
The association between clinicopathological factors at initial diagnosis and PSA recurrence
To investigate factors related to PSA recurrence, which may reflect the outcome of the first therapy, the following sub-group analyses were performed by iPSA level, cT stage and GS of biopsy specimens. There was no significant difference among cT stage, biopsy GS and Pearson's chi-square test. RP, radical prostatectomy; NEH, Neoadjuvant ADT followed by EBRT and HDR. bRFS in patients treated with the three treatment modalities ( Supplementary Fig. 1A-F) .
Among patients treated with NEH (Fig. 1C) , the 5y-bRFS rate of the high-iPSA (PSA > 50 ng/ml) group was significantly lower (54.7%, n = 37) than the low-(PSA ≤ 20 ng/ml; 85.7%, n = 96, P < 0.001) and intermediate-iPSA groups (20 ng/ml < PSA ≤ 50 ng/ ml; 84.7%, n = 57, P = 0.012). The bRFS of the intermediate-iPSA group was similar to the low-iPSA group (P = 0.314).
Among patients treated with IMRT ( Fig. 1D) , 5y-bRFS rates were 75.7% in the low-(n = 51), 80.6% in the intermediate-(n = 33) and 29.0% in the high-iPSA groups (n = 21). bRFS was significant only between the low-and high-iPSA groups (P = 0.022).
Among patients treated with RP (Fig. 1E) , the curves appear to be stratified: 61.4% in the low-(n = 90), 38.7% in the intermediate-(n = 60) and 25.0% in the high-iPSA groups (n = 4). bRFS was significant only between the low-and intermediate-iPSA groups (P = 0.012); however, there was no difference between the intermediateand high-iPSA groups (P = 0.402). According to PSA level, the rates of patients with a positive resection margin (RM) were 48.9% (n = 44) in the low-, 61.7% (n = 37) in the intermediate-and 100% (n = 4) in the high-iPSA groups; the rates of patients with lymph node metastasis were 6.7% (n = 6) in the low-, 5.0% (n = 3) in the intermediate-and 0% (n = 0) in the high-iPSA groups.
Next, using multivariate analysis, we analyzed the association among pre-treatment risk factors (age [≥70 vs. Table S1 ). 
Toxicities caused by NEH
Discussion
Several investigators showed that the combination of HDR-BT, EBRT and ADT yielded good treatment results in high-risk PCa patients (8, 9) . Our study retrospectively analyzed the relationship among several clinicopathological factors and treatment outcomes in high-risk PCa patients treated with NEH (neoadjuvant ADT for 3-6 months, EBRT [39 Gy in 13 fractions] and HDR-BT [18 Gy in two fractions] without adjuvant ADT) and evaluated treatment efficacy compared with other treatment modalities (IMRT plus ADT and RP) performed during the same period. The incidence and severity of urinary and bowel NEH toxicities in the current study were considered comparable to those of IMRT reported in the literature (10) . and RP groups (E) according to iPSA levels (PSA ≤ 20 ng/ml, 20 ng/ml < PSA ≤ 50 ng/ml and PSA > 50 ng/ml). *P value is below 0.05.
Although the patient backgrounds were different among the three treatment groups, this study suggested that NEH yielded favorable treatment outcomes (Fig. 1A and B) . When comparing the outcomes of NEH by iPSA level, more favorable bRFS was obtained in patients with iPSA <50 ng/ml than those with iPSA >50 ng/ml (Fig. 1C) . From the results, it was considered that NEH without long adjuvant ADT may be effective for high-risk PCa patients with iPSA <50 ng/ml, at least for short follow-up. It was also considered that the very high radiation dose delivered to the PCa by the combination of EBRT and HDR-BT may have contributed to the favorable treatment outcomes (5) . According to the NCCN guidelines (1), long-term ADT adding brachytherapy and EBRT is not always needed for patients at high risk of recurrence. The optimal duration of ADT in this setting remains unclear. Based on the results of the current study, it was suggested that short-term ADT may be sufficient to achieve better PSA recurrence-free survival for high-risk patients with PSA <50 ng/ml. Further long duration of follow-up is needed to investigate the cancer-specific survival between with and without adjuvant ADT for those patients treated with NEH. On the other hand, patients with PSA >50 ng/ml may have micrometastases, even if there are no apparent metastatic lesions in imaging studies. Adjuvant long-term ADT (11) and/or pelvic lymph node irradiation (12) may have a potential benefit for these highrisk PCa patients with high-iPSA treated by NEH.
As for RP, in our cohort, the iPSA level was associated with the rate of positive RM and bRFS, suggesting that neoadjuvant ADT using an luteinizing hormone releasing hormone (LH-RH) analogue may contribute to reducing the risk of positive RM for high-risk PCa patients with higher iPSA. Although neoadjuvant ADT before RP has not been recommended yet, recent reports indicate that it may be applicable for limited high-risk PCa patients treated with RP (13, 14) . Further study is needed to select appropriate high-risk PCa patients for neoadjuvant treatment before RP.
Regarding cT stage or biopsy GS, we did not find the expected results in each treatment group, possibly due to the low quality of the examinations, (e.g. low resolution imaging studies, cT staging based on a digital rectum examination without an imaging study and biopsy GS by a non-targeting random biopsy without referring to imaging [the concordance rate of GS between biopsy and surgical specimens was 38.1% in our RP group]), which were standard methods before 2012.
There are some limitations to our study. Clinical outcomes among radiotherapies and RP were not strictly compared for highrisk PCa patients for the following reasons: heterogeneous cohort, difference in treatment areas (i.e. RP is suitable for pelvic lymph nodes, but radiotherapy is not), with or without (neo-)adjuvant ADT, different prescription dose in the IMRT group and different definitions of biochemical outcome. These are major limitations of this retrospective study. Therefore, a prospective study based on a definitive treatment schedule is needed to investigate differences in clinical outcomes between surgery and radiotherapy.
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